The PROPHECY study will evaluate antibody and cellular immune responses after infection or vaccination in healthy and vulnerable people to evaluate their protection against future variants.
2022-2026
We will comprehensively profile the immune responses to SARS-CoV-2 using clinical samples collected from 11 vulnerable and immunocompromised cohorts (Adults and Paediatrics) and healthy individuals who have been vaccinated. Serological antibody responses and cellular responses T-cells and B-cell will be measured.
Generating knowledge and evidence to improve vaccine schedules, future booster strategies and improved access to clinical care for vulnerable populations. In addition, our findings will inform future clinical trials to enhance vaccine responses in immunocompromised people.
Doctor Gabriela Khoury
Contact Doctor Gabriela Khoury for more information about this project.
Funding
Partners
- Medical Research Future Fund (MRFF): 2021 COVID-19 Treatment Access and Public Health Activities.
Partners +
Collaborators
- Alfred Health: A/Prof James McMahon, Professor Anne Holland, Professor David Curtis, A/Prof Miles Sparrow.
- Monash Health: A/Prof Benjamin Rogers, A/Prof William Mulley, A/Prof Ian Woolley, A/Prof Alberta Hoi, Dr Samar Ojaimi, Dr Edward Giles
- Monash University: Prof Menno Van Zelm, A/Prof James Trauer
- Murdoch Children’s Research Institute: A/Prof Paul Licciardi
- Consumer Health Partners: Spleen Australia, AusPIPS, National Association of people with HIV Australia, Musculoskeletal (MSK) Australia, Crohn’s and Colitis Australia and Safer Care Victoria
Project
Team
Meet the project team. Together, we are translating research into better health, for all.
